IV 
117TH CONGRESS 
1ST SESSION 
H. RES. 740 
Recognizing October 2021 as Liver Cancer Awareness Month. 
IN THE HOUSE OF REPRESENTATIVES 
OCTOBER 21, 2021 
Ms. VELA´ZQUEZ (for herself, Mr. FITZPATRICK, and Mr. ESPAILLAT) sub-
mitted the following resolution; which was referred to the Committee on 
Energy and Commerce 
RESOLUTION 
Recognizing October 2021 as Liver Cancer Awareness 
Month. 
Whereas liver cancers, and risk factors causing such diseases, 
have become urgent problems of global proportion; 
Whereas in the United States, liver cancer is the fastest- 
growing cause of cancer-related death and is among the 
leading causes of cancer-related deaths; 
Whereas in the United States, the Division of Cancer Control 
and Population Sciences of the National Cancer Institute 
estimated that there will be 42,230 new liver cancer diag-
noses in the year 2021, and approximately 30,200 will 
die from the disease; 
Whereas liver cancer cases are projected to increase 35 per-
cent in the United States; 
VerDate Sep 11 2014 
02:10 Oct 22, 2021
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR740.IH
HR740
kjohnson on DSK79L0C42PROD with BILLS
•HRES 740 IH 
Whereas, on average, between 20 to 30 percent of individuals 
with chronic hepatitis B infection, 4 percent of individ-
uals with hepatitis C, 20 percent of individuals with hep-
atitis C-cirrhosis, between 4 to 27 percent of individuals 
with nonalcoholic steatohepatitis, and between 10 to 15 
percent of individuals with alcohol-related cirrhosis will 
develop liver cancer; 
Whereas American Indian and Alaska Natives are more than 
twice as likely to develop liver cancer when compared to 
non-Hispanic Whites; 
Whereas American Indian, Alaska Native, Hispanic, Native 
American Pacific Islander and Black men and women are 
at greater risk of developing liver cancer as compared to 
the White (Hispanic and non-Hispanic) population; 
Whereas among the Native American Pacific Islander popu-
lation, the higher rate of liver cancer is partially ex-
plained by higher incidence rates of hepatitis B and dia-
betes, which are comorbidities shown to increase the risk 
of developing liver cancer in an individual; 
Whereas the largest increase of liver cancer rates by 2030 is 
projected to be among African-American men and 
women; and 
Whereas the goals of ‘‘Liver Cancer Awareness Month’’ dur-
ing October 2021 are to— 
(1) highlight the global impact of liver cancer and 
the risk for all people with liver disease; 
(2) recognize that 70 percent of liver cancer cases 
could potentially be prevented and eliminated in part 
through a comprehensive public education and awareness 
campaign designed to identify those at risk for, and living 
with, liver cancer; 
VerDate Sep 11 2014 
02:10 Oct 22, 2021
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR740.IH
HR740
kjohnson on DSK79L0C42PROD with BILLS
•HRES 740 IH 
(3) inform patients about new treatments and clin-
ical trials that are available for liver cancer; and 
(4) help increase the length and quality of life for 
people diagnosed with liver cancer: Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) supports broad access to treatments of and 
testing for the greatest risk factors for liver cancer, 
including the hepatitis B virus, the hepatitis C virus, 
nonalcoholic 
fatty 
liver 
disease, 
nonalcoholic 
steatohepatitis, alcohol-related cirrhosis, and other 
related liver conditions; 
(2) supports raising awareness of the risks and 
consequences of undiagnosed liver cancer, the impor-
tance of screening at-risk populations, and the value 
of diagnosing early; 
(3) calls for a robust governmental and public 
health response to protect the health of the approxi-
mately 45,000 people in the United States who cur-
rently have liver cancer; and 
(4) urges the Director of the Centers for Dis-
ease Control and Prevention to partner with State 
and local health departments to develop strategies to 
address risk factors for liver cancer and related liver 
diseases, including expanding access to hepatitis B 
vaccination, and access to available treatments of 
and testing for hepatitis C, nonalcoholic fatty liver 
VerDate Sep 11 2014 
02:10 Oct 22, 2021
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR740.IH
HR740
kjohnson on DSK79L0C42PROD with BILLS